AgeX Therapeutics, Inc. (AGE) shares are declining more than 33 percent on Friday morning trade, continuing a bearish trend.
There have been no stock-impacting news so far today.
On the other hand, today AgeX's subsidiary clinical-stage biotechnology company Serina Therapeutics announced a POZ polymer technology license agreement with Pfizer.
Currently, AGE is at $0.41, down 33.48 percent from the previous close of $0.58 on a volume of 8,421,315.
For comments and feedback contact: editorial@rttnews.com
Business News